Compare HROW & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | STAA |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 1995 |
| Metric | HROW | STAA |
|---|---|---|
| Price | $38.00 | $22.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $69.86 | $22.81 |
| AVG Volume (30 Days) | 614.5K | ★ 879.5K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $239,442,000.00 |
| Revenue This Year | $31.62 | $30.82 |
| Revenue Next Year | $50.77 | $8.41 |
| P/E Ratio | ★ N/A | $233.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.54 | $15.59 |
| 52 Week High | $54.98 | $35.87 |
| Indicator | HROW | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 31.57 |
| Support Level | $37.81 | $16.49 |
| Resistance Level | $41.94 | $27.53 |
| Average True Range (ATR) | 2.28 | 1.46 |
| MACD | -0.87 | -0.44 |
| Stochastic Oscillator | 6.61 | 3.77 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.